PharmacoEconomics (2017) 35:845–858 DOI 10.1007/s40273-017-0519-z ORIGINAL RESEARCH ARTICLE Using Genomic Information to Guide Ibrutinib Treatment Decisions in Chronic Lymphocytic Leukaemia: A Cost-Effectiveness Analysis 1 1 2,3 2 • • • • James Buchanan Sarah Wordsworth Ruth Clifford Pauline Robbe 4,5 2,3,4,6 4,5 • • Jenny C. Taylor Anna Schuh Samantha J. L. Knight Published online: 31 July 2017 The Author(s) 2017. This article is an open access publication Abstract Results Genomic testing strategies yielded the most life- Background Genomic tests may improve the stratiﬁcation years/quality-adjusted life-years per patient, but were not of patients to receive new therapies in several disease cost effective compared with a threshold of £30,000 per life- areas. However, the use of expensive targeted therapies can year/quality-adjusted life-year gained. Cost-effectiveness impact on the cost effectiveness of these tests. This study acceptability curves indicated that there was some uncer- presents an economic evaluation of genomic testing in tainty surrounding this result. A genomic testing strategy chronic lymphocytic leukaemia in the context of the UK becomes the most cost-effective option if a higher end-of-life National Health Service. cost-effectiveness threshold of £50,000 is applied, if a Methods Cost-effectiveness and cost-utility analyses (us- societal costing perspective is considered in 25-year-old
PharmacoEconomics – Springer Journals
Published: Jul 31, 2017
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera